Diversified Consumer Services
Company Overview of University of Pennsylvania
University of Pennsylvania is an educational institution that offers graduate, undergraduate, professional, summer courses, and distance learning programs in the fields of law, medicines, communication, and dental medicine. The institution was founded in 1740 and is based in Philadelphia, Pennsylvania.
34th and Spruce Streets
Philadelphia, PA 19104
Founded in 1740
Key Executives for University of Pennsylvania
Dean of the School of Design
Associate, Licensing and New Business Start-Up at Center for Technology Transfer
Compensation as of Fiscal Year 2016.
University of Pennsylvania Key Developments
BluePen Biomarkers Announces Collaboration with the University of Pennsylvania to Develop Strategic 'Multi-Omics' Platform for Integrated Biomarker Discovery
Jun 7 16
The University of Pennsylvania has co-founded and structured BluePen Biomarkers in collaboration with Blueprint Bio, Inc. and Emerald Logic, Inc. to conduct biomarker research and identification. BluePen is creating a comprehensive biomarker measurement and discovery pipeline for the acceleration of personalised medicine. BluePen will collaborate with Ian Blair, PhD, the A.N. Richards Professor of Systems Pharmacology and Translational Therapeutics and Director of Center for Cancer Pharmacology in the Perelman School of Medicine at the University of Pennsylvania. BluePen will measure and integrate genomic, proteomic, metabolomic, and lipidomic biomarkers, alongside clinical data, demographics, and other phenotypic data, providing its customers and collaborators with access to a comprehensive 'multi-omics' discoveryplatform. With this collaborative venture, Penn's goal is to radically improve and accelerate the discovery of relevant biomarkers, without bias toward single genes, single modalities, or inappropriate mathematical assumptions.
Biogen Announces Collaboration and Alliance with the University of Pennsylvania to Advance Gene Therapy and Gene Editing Technologies
May 16 16
Biogen announced a broad collaboration and alliance with the University of Pennsylvania to advance gene therapy and gene editing technologies. The research and translational development collaboration has multiple objectives, but will primarily focus on the development of therapeutic approaches that target the eye, skeletal muscle and the central nervous system. Another important aspect of the alliance will focus on validating next-generation gene transfer technology using adeno-associated virus gene delivery vectors. The collaboration will also explore the expanded use of genome editing technology - the insertion, deletion or replacement of DNA in the genome of an organism - as a potential therapeutic platform.
Seres Therapeutics, Inc. Announces Collaboration with University of Pennsylvania Researchers to Support the Development of Microbiome Therapeutics for Rare Genetic Metabolic Diseases and Inflammatory Bowel Disease
May 12 16
Seres Therapeutics, Inc. announced that it has entered into a multi-year collaboration with leading microbiome clinical-scientists from the University of Pennsylvania (Penn) to support the development of novel treatment approaches for certain rare genetic metabolic diseases including urea cycle disorders, and inflammatory bowel disease (IBD). Under the terms of the agreement, Penn Professors Gary D. Wu, M.D., and James Lewis, M.D., two global leaders in the field of the microbiome, plan to conduct investigator sponsored research evaluating rationally designed bacterial compositions for patients with ulcerative colitis. In a separate study, the Penn team agreed to collaborate with Seres to evaluate the role of the microbiome in certain rare genetic metabolic diseases, beginning with urea cycle disorders. This clinical study is designed to build upon published results suggesting that altering the gut microbiome may reduce toxic levels of ammonia in patients with urea cycle disorders. Findings from these studies are expected to be used in the design of Ecobiotic microbiome therapeutic candidates to interdict in these rare genetic disorders.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|